Bioscience (P2D) is a specialty pharmaceutical company focused on developing innovative drugs for the treatment of central
nervous system (CNS) inflammatory disorders including Frontotemporal Dementia (FTD) and Alzheimer’s disease (AD).
At P2D, our experienced drug development team utilizes
“Targeted Phenotypic Screening” and transgenic preclinical models of neurodegenerative diseases to accelerate
our drug development process. Our goal is to advance a product candidate through preclinical efficacy testing, GLP-safety
studies and early clinical safety and clinical proof-of-concept studies then seek partners to complete the clinical development
and commercialization process.
P2D currently has a pipeline of drug candidates that are: 1) orally and centrally active
isoindoline TNFα inhibitors for the treatment FTD and AD and 2) benztropine-analog DAT inhibitors for the treatment
of Attention Deficit/Hyperactivity Disorder (ADHD).